Literature DB >> 23706170

Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas.

Oluwole Fadare1, Samuel James, Mohamed M Desouki, Dineo Khabele.   

Abstract

The purpose of this study is to assess whether composite or coordinate immunoexpression patterns of estrogen receptor (ER), progesterone receptor (PR), and Wilms tumor 1 (WT1) gene can significantly distinguish between endometrial serous carcinoma (ESC) and ovarian serous carcinoma (OSC). Immunohistochemical analyses were performed on whole tissue sections from 22 uterus-confined ESCs and on a tissue microarray of 140 high-grade, pan-stage OSCs, using antibodies to ER, PR, and WT-1. Estrogen receptor, PR, and WT1 expressions were present in 37%, 49%, and 81% of OSC, respectively, but these markers were also present in 18%, 27%, and 36% of ESC. The ER+/PR+/WT1+ coordinate profile was identified in 33.6% of OSC but in none of ESC (P = .0006), resulting in a calculated sensitivity and specificity of this profile for OSC of 33.6% and 100%, respectively. By contrast, the ER-/PR-/WT1- coordinate profile was identified in 41% of ESC but in only 6.4% of OSC (P = .0001), resulting in a calculated sensitivity and specificity of this profile for ESC of 50% and 94%. In summary, in the differential diagnosis between OSC and ESC, positivity for all 3 markers favors an extrauterine origin, whereas negativity for all 3 markers is supportive of an endometrial origin. The use of single markers for this purpose is not recommended, as each lacks optimal discriminatory power. Coordinate profiles, in general, have a high specificity but low sensitivity in this differential diagnosis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Estrogen receptor; Progesterone receptor; Serous carcinoma; WT1

Mesh:

Substances:

Year:  2013        PMID: 23706170      PMCID: PMC4079538          DOI: 10.1016/j.anndiagpath.2013.04.011

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  17 in total

Review 1.  WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract.

Authors:  W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2004-04       Impact factor: 2.762

2.  Neoadjuvant chemotherapy in uterine papillary serous carcinoma.

Authors:  E Resnik; J B Taxy
Journal:  Gynecol Oncol       Date:  1996-07       Impact factor: 5.482

3.  WT1, p53 and hormone receptor expression in uterine serous carcinoma.

Authors:  Lynn Hirschowitz; Raji Ganesan; W Glenn McCluggage
Journal:  Histopathology       Date:  2009-10       Impact factor: 5.087

Review 4.  Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.

Authors:  S Kounelis; N Kapranos; E Kouri; D Coppola; H Papadaki; M W Jones
Journal:  Mod Pathol       Date:  2000-04       Impact factor: 7.842

5.  Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations.

Authors:  M L Carcangiu; J T Chambers; I M Voynick; M Pirro; P E Schwartz
Journal:  Am J Clin Pathol       Date:  1990-09       Impact factor: 2.493

6.  Comparative analysis of histologic homologues of endometrial and ovarian carcinoma.

Authors:  R F Caduff; S M Svoboda-Newman; R E Bartos; A W Ferguson; T S Frank
Journal:  Am J Surg Pathol       Date:  1998-03       Impact factor: 6.394

7.  WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.

Authors:  Neal S Goldstein; Alison Uzieblo
Journal:  Am J Clin Pathol       Date:  2002-04       Impact factor: 2.493

8.  WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.

Authors:  Geza Acs; Theresa Pasha; Paul J Zhang
Journal:  Int J Gynecol Pathol       Date:  2004-04       Impact factor: 2.762

9.  Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.

Authors:  Jakob Dupont; Xi Wang; David S Marshall; Mario Leitao; Cyrus V Hedvat; Amanda Hummer; Howard Thaler; Richard J O'Reilly; Robert A Soslow
Journal:  Gynecol Oncol       Date:  2004-08       Impact factor: 5.482

Review 10.  Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects.

Authors:  Philip B Clement; Robert H Young
Journal:  Adv Anat Pathol       Date:  2004-05       Impact factor: 3.875

View more
  1 in total

1.  Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Authors:  Makoto Kodaira; Kan Yonemori; Tatsunori Shimoi; Akihiko Yoshida; Masayuki Yoshida; Atsuko Kitano; Akihiko Shimomura; Mayu Yunokawa; Chikako Shimizu; Yuichi Takiguchi; Yasuhiro Fujiwara; Kenji Tamura
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.